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to be diagnosed with advanced BC and to have the highest mortality rates and 
the poorest survival rates from BC. The purpose of the study is to determine the 
relationship among race, insurance, and BC death. METHODS: African Americans 
and Non-Hispanic Whites female BC patients diagnosed between 2007 and 2010 
in Florida, and treated at a network of 9 hospitals were identified by electronic 
medical record search. BC incidence cases were obtained from Florida Cancer 
Data System (FCDS) which is the largest population-based cancer incidence reg-
istry in the nation. FCDS cases were linked to Electronic Medical Records (EMRs). 
Cause specific survival was the major Outcome measure. Nonparametric survival 
curves for the various insurance categories were generated using the Kaplan-
Meier method. Socio-demographics included age at diagnosis, race, insurance, 
marital status, poverty level. Tumor characteristics consisted of tumor stage, 
tumor grade, tumor size, estrogen receptor status, progesterone receptor status. 
Risk of BC death was first examined as a function of insurance status. Hazard 
ratios were then obtained using Cox proportional hazards model after adjust-
ing for socio-demographics, tumor characteristics when associating insurance 
status with BC related death. RESULTS: Study population was older (74% more 
than 50 years old), had more whites, 55.55 % were married and included a greater 
proportion of patients on public coverage (46%). Survival was worse for uninsured 
patients than for privately insured patients with all stages. The adjusted risk 
of BC death was 40% higher for uninsured patients than for privately insured 
patients. CONCLUSIONS: Uninsured patients presented with worse survival than 
did privately insured patients. Findings from this study demonstrate that patients 
without insurance experience worse outcomes and would benefit the most from 
improved access to screening and optimal cancer care.
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OBJECTIVES: Peripheral arterial disease (PAD) is a high prevalence disease after 50 
years old, with considerable impact in quality of life, productivity, disability and 
longevity. Screening program for high risk populations followed by risk factors modi-
fication seems to be a cost effective strategy, but adherence to treatment is crucial 
to achieve clinical and financial goals. The aim of this study was to evaluate the 
minimal adherence rate, to risk factors drugs modification to achieve the return 
of investment for screening-management programs in the Brazilian public health 
system context. METHODS: a decision tree – return of investment model was devel-
oped in Excel® to analyze the impact of implementing a screening-management 
program for early detection and risk management modifications in peripheral arte-
rial disease. Effectiveness of drugs to control the risk factor and reduce the risk of 
major cardiovascular events and major leg events was extracted from literature. 
Direct costs included treatment cost, exams, physician visits and events (AMI and 
Stroke), indirect cost was calculated considering the loose of productivity. The sys-
tem overload with screening program, including physician visits and exams were 
considered in the model. RESULTS: Our hypothetical population was 2.844.201 
subjects from Rio de Janeiro city, with a prevalence of PAD after 55 years old of 
10% (133.185) and the prevalence of intermittent claudication of 5%(66.592). The 
total cost of implementing the screening-risk management program for the entire 
population was R$8.576.758.52, the financial equilibrium was achieved with full 
adherence of 46,3% of subjects, with a reduction of R$4.201.429,36 with system effi-
ciency improvement, R$4.395.630,65 with indirect costs reductions and R$738.565,00 
with direct costs reductions. CONCLUSIONS: A screening-risk factor management 
program for improve the quality of assistance for PAD is feasible in the Brazilian 
public health system context and achieve its equilibrium with full adherence to risk 
factor management of 46,3% of subjects.
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OBJECTIVES: This study analyzes the cost of adverse events associated with meta-
static renal cell carcinoma (mRCC) treatments of pazopanib and sunitinib. METHODS: 
A cost analysis was performed based on the published data of the COMPARZ study. 
All adverse events (AEs) were identified based on the AEs reported in this study, 
Cost information related to the the treatment of the most frequent adverse events 
(> 15%) in the study population (n= 1,100 individuals) were obtained. These events 
included in the analysis were hepatotoxicity, anemia, nausea, fatigue and diarrhea. 
The perspective adopted in this analysis was of the Unified Health System (SUS) and 
Brazilian Supplementary Healthcare (SS). For reckoning purposes, the Medication 
Market Regulation Chamber (CMED/ ANVISA) listed prices were used. RESULTS: 
Were obtained the following results for suninitib vs pazopanib treatment course 
respectively: In SUS perspective: Increased ALT (BRL 107,24 / BRL 149,63), Anemia 
(BRL 47,72 / BRL 24,65), Diarrhea (BRL 231,44 / BRL 255,8), Fatigue (BRL 22,67 / BRL 
19,79), Hypertension (BRL 618,79 / BRL 694,26), Nausea (BRL 176,49 / BRL 172,65), 
Thrombocytopenia (BRL 66,29 vs BRL 34,85). When considering costs incurred 
from private pay perspective such as SS, we observed the values were Increased 
ALT (BRL 810,84 / BRL 1131,40), Anemia (BRL 269,31 / BRL 139,14), Diarrhea (BRL 
787,41 vs BRL 870,29), Fatigue (BRL 205,51 / BRL 179,42), Hypertension (BRL 1017,91 
/ BRL 1142,04), Nausea (BRL 782 / BRL 765), Thrombocytopenia (BRL 328,49 / BRL 
172,67). CONCLUSIONS: A therapy that has less financial impact on the treatment of 
adverse events is the choice of sunitinib for both public (6% decrease) and private (5%).
OBJECTIVES: To estimate burden of disease of hepatitis C (HVC) infection in 
Colombia METHODS: Different research methodologies were uses: system-
atic literature review methodology to identify parameters of disease frequency 
described in national and international studies. For all calculations the popula-
tion of Colombia was taken as projections National Administrative Department 
of Statistics. Other important source of information was the burden of disease 
studies conducted by the Institute for Health Metrics and Evaluation (IHME) at the 
University of Washington. RESULTS: In Colombia are estimated between 250,000 
and 350,000 people HCV carriers, currently. Of these, annually are attended in the 
General System of Social Security in Health, between 1100 and 1500 patients. The 
deaths expected by Liver cirrhosis secondary to hepatitis C are between 1,400 and 
1,600. By other side, the deaths annually associated with Liver Cancer related with 
Hepatitis C are between 750 and 850 deaths. This would generate about 40,000 and 
55,000 DALYs representing the between 84.8 and 106.1 DALYs per 100,000 people in 
Colombia in 2014. CONCLUSIONS: The burden of disease Hepatitis C in Colombia 
show that it is a public health problem important for the health system and society.
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OBJECTIVES: To determine clinical, socio-demographic and member-level fac-
tors associated with hospital readmissions in COPD patients and identify COPD 
patients at high risk of two or more hospital readmissions within 6 months post-
discharge. METHODS: Commercial and Medicare health plan members who were 
identified with COPD and incurred an index admission for a COPD-related condition 
from August 2011 through July 2013 in Southeastern Pennsylvania and surrounding 
counties were prospectively evaluated using health insurance claims and consumer 
data. COPD patients were identified using clinical diagnoses defined by Centers 
for Medicare and Medicaid Services. Readmission was defined as two or more all-
cause hospital admissions within 6 months after the index admission. Risk factors 
including but not limited to utilization, pharmacy, comorbidities, laboratory results, 
and vaccinations were examined and measured up to one year prior to the index 
admission and during the hospitalization. Socio-demographic and member-level 
factors were also evaluated for model predictability. RESULTS: Within 6 months 
post-discharge, of the 7,206 COPD patients, 7.7% had two or more readmissions. 
Bivariate analysis found that comorbidities and utilization were large predictors of 
readmissions. Additional significant factors included oxygen use, B-type natriuretic 
peptide testing, quinolone antibiotic use and education level. Multivariate analysis 
using logistic regression found prior admissions, ER visits, specialist visits, comorbid 
with cellulitis, myocardial infarction, renal disease, diabetes and low education to be 
among the highly predictive variables. The model yielded a lift of 3.1 for the top 5% of 
the population and produced a Positive Predictive Value of 27%. CONCLUSIONS: Our 
model identified specific combinations of clinical, socio-demographic and member-
level factors that improved our ability to identify COPD patients at the highest risk 
of readmission. Further research is needed to validate model results and apply 
clinical analytics into intervention and outreach programs aimed at preventing 
future readmissions.
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OBJECTIVES: To analyze the association between non-pharmacological treatment 
of substance use and mortality in elderly Medicare patients with advanced pros-
tate cancer and substance use disorder. METHODS: SEER-Medicare linked database 
between 2000 and 2009 was used. From the cohort of men diagnosed with advanced 
prostate cancer between 2001 and 2004, we identified those with a diagnosis of sub-
stance use using ICD-9 codes of 291 (Alcoholic psychosis); 292 (Drug psychoses); 303 
(Alcohol dependence syndrome); 304 (Drug dependence); and 305 (Non-dependent 
use of drugs). For this cohort of elderly with advanced prostate cancer and substance 
use, we used inpatient, outpatient and provider claims to determine non-phar-
macological treatment for substance use. The association between treatment for 
substance use and five-year mortality was analyzed using Cox regression. RESULTS: 
Of 1509 elderly with advanced prostate cancer and substance use disorder, only 
10% had a claim related to non-pharmacological treatment of substance use in 
the five-year period post-cancer diagnosis. Demographic and clinical attributes 
were comparable between those treated for substance use vs. those not treated 
for substance use. Cox regression indicated that treatment for substance use was 
associated with lower hazard of all-cause mortality, compared to those not treated 
for substance use (HR 0.63 ; 95% CI 0.46, 0.86). CONCLUSIONS: In elderly prostate 
cancer patients with substance use disorder, substance use treatment appears to 
have beneficial effect on mortality. However, the utilization of substance use treat-
ment was only moderate. Prostate cancer incidence increases exponentially with 
age and therefore, an aging population will exert significant burden on healthcare 
system. Substance use disorder remains a neglected co-morbidity in elderly cancer 
patients. Along with policies to effectively screen and treat substance use in elderly 
prostate cancer patients, policies for enhancing utilization of substance use treat-
ment by elderly cancer patients are necessary.
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OBJECTIVES: Breast cancer (BC) poses disproportionate burden of disease among 
medically underserved and minority women. African-American women continue 
